FDA MEDIA ADVISORY - Briefing on ESAs Safety Information

Wednesday, February 17, 2010 General News
Email Print This Page Comment
Font : A-A+



** CREDENTIALED PRESS ONLY **

WHAT:

A briefing on a new risk management program for erythropoiesis-stimulating agents (ESAs), which are used to treat anemia in certain patients

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

WHO:

-- Richard Pazdur, M.D., director, Office of Oncology Drug Products, Center for Drug Evaluation and Research (CDER), FDA

-- Patricia Keegan, M.D., director, Division of Biologic Oncology Products, CDER, FDA

-- Dwaine Rieves, M.D., director, Division of Medical Imaging and Hematology Products, CDER, FDA

-- Jeff Summers, M.D., deputy director for safety, Division of Biologic Oncology Products, CDER, FDA

WHEN:

Tue., Feb. 16, 2010, 1:00 p.m. EST

HOW:

Reporters may participate in a listen-only mode by dialing 888-995-9712 or for international reporters, 1-630-395-0260. The password for all callers is "FDA." A replay of the briefing will be available until Feb. 23 by calling 800-391-9845 or for international reporters, 1-203-369-3267.

CONTACT: Karen Riley, +1-301-796-4674, karen.riley@fda.hhs.gov, or Erica Jefferson, +1-301-796-4988, erica.jefferson@fda.hhs.gov, both of the U.S. Food and Drug Administration

/PRNewswire-USNewswire -- Feb. 16/

SOURCE U.S. Food and Drug Administration


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook